BRCA2 and neoplasm: Moreover, as replication stress is a common consequence of chemotherapy (e.g., cisplatin) and PARP inhibition, our data raise the possibility that such treatments may inadvertently activate A3B-mediated mutagenesis in BRCA2-deficient tumors, potentially contributing to therapy resistance or tumor evolution.